FDA — authorised 8 August 2018
- Application: BLA761051
- Marketing authorisation holder: KYOWA KIRIN
- Local brand name: POTELIGEO
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Mogamulizumab-Kpkc in United States
FDA authorised Mogamulizumab-Kpkc on 8 August 2018
Marketing authorisation
Mogamulizumab-Kpkc in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Mogamulizumab-Kpkc approved in United States?
Yes. FDA authorised it on 8 August 2018.
Who is the marketing authorisation holder for Mogamulizumab-Kpkc in United States?
KYOWA KIRIN holds the US marketing authorisation.